Journal: Transfusion Medicine and Hemotherapy
Submission Deadline: December 31, 2025
Biomedical engineering is a rapidly evolving field and is of utmost importance for the field of transfusion medicine. We aim to highlight developments of engineered blood products — innovative substitutes and enhancements for natural blood components. These products could offer solutions to address blood shortages, transfusion-transmitted infections, and the limitations of donor-derived blood.
This article collection welcomes original research articles, reviews, case studies, and perspectives focused on the latest advances in the design, production, and application of engineered blood products.
Topics of interest include, but are not limited to:
- Artificial red blood cells and oxygen carriers
- Engineered platelets and hemostatic agents
- Synthetic or recombinant plasma components
- Cell-free hemoglobin and hemoglobin-based oxygen carriers (HBOCs)
- Stem cell-derived blood components
- Immunomodulatory and therapeutic blood substitutes
- Nanotechnology and biomaterials in blood product engineering
- Clinical trials and regulatory challenges
- Biomanufacturing and scalability
- Ethical, economic, and supply chain considerations
We look forward to your contributions in advancing this transformative field.
Please select the option “Call for Papers: Engineered Blood Products” when submitting your manuscript and mention this Call for Papers in your cover letter.
Article publication is subject to rigorous peer review in line with the journal's editorial policies. Please refer to our author guidelines for further details about the publication conditions.
Karger Publishers has established agreements with consortia and institutions that include full or partial coverage of Article Processing Charges (APC). Corresponding authors can publish Open Access articles at no or reduced cost if they are associated with or employed by one of these universities/institutions.